Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Harbour BioMed Collaborates with WuXi Biologic for Supply of Novel Antibody

publication date: Jun 25, 2018

Harbour BioMed has formed an "initial strategic" collaboration with WuXi Biologics to develop clinical trial supplies of Harbour's leading HCAb antibody. Harbour, headquartered in the Boston area with a development facility in Shanghai, launched 18 months ago to develop IO and immunology therapies. Harbour BioMed was funded with $50 million in startup capital and included an existing Dutch discovery company, Harbour Antibodies BV. Harbour and WuXi Biologics will develop the HCAb antibody candidate for China and other global markets. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.